EGFR and cancer: Recent studies suggest that DUOX1 silencing in cancers is associated with worse prognosis, and that loss of epithelial DUOX1 promotes features of epithelial-to-mesenchymal transition (EMT), invasive properties, as well as enhanced cancer stem-cellness and resistance to the EGFR tyrosine kinase inhibitor erlotinib5,9.